HomeAI · summaries
Storia in 2 fonti
Allogene CEO to step down; Agios drug fails key test
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Allogene CEO to step down; Agios drug fails key test
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA…
- ·
endpoints.news
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by the company’s…